In the latest edition of pharmind (87, No. 6/2025), Dr. Julia Traumann and Dr. Markus Grammel publish the second part of their article on the new European Unitary Patent System. Following the general overview in Part 1, Part 2 focuses on initial decisions by the Unified Patent Court from the pharmaceutical and life sciences sector.
The article highlights a selection of early cases, including:
- Amgen / Sanofi & Regeneron (Praluent®)
- Alexion / Amgen & Samsung Bioepis (Soliris®)
- Novartis & Genentech / Celltrion (Xolair®)
Each case is examined with regard to specific factual, procedural or legal aspects.